FlandersBio on Twitter

Follow us on Twitter

Archive for December 2014 - News

Archive for December 2014 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

29.12.2014

Ablynx [Euronext Brussels: ABLX], today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Biotech Value Fund Partners LP and Biotech Value Fund Inc. read more

ThromboGenics to Present at the J.P. Morgan Annual Healthcare Conference 2015 in San Francisco

29.12.2014

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that its Chief Executive Officer Dr Patrik De Haes will be presenting at the 33rd J.P. Morgan Annual Healthcare Conference (12-15 January, 2015). read more

TiGenix submits its pivotal US trial design for Cx601 to the FDA for Special Protocol Assessment

22.12.2014

TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today that it has submitted to the Food and Drug Administration (FDA) the required documentation for a Special Protocol Assessment (SPA) of its pivotal Phase III trial design for Cx601 in the treatment of complex perianal fistulas in patients with Crohn's disease in the United States. Agreement with the FDA on the SPA will ensure that the trial design is aligned with the FDA's requirements for the future approval of Cx601. read more

CARDIO3 BIOSCIENCES ANNOUNCES THE ENROLMENT OF THE 240TH PATIENT FOR ITS CHART-1 PHASE III CLINICAL TRIAL FOR THE TREATMENT OF HEART FAILURE

19.12.2014

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today the enrolment of the 240th patient in its CHART-1 European trial for C-Cure®, the first and only stem cell therapeutic using guided stem cells for the treatment of congestive heart failure. read more

Galapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbVie

19.12.2014

Galapagos NV (Euronext: GLPG) announces the initiation of the first Phase 1 study with GLPG1837. This novel potentiator is designed as a CFTR targeted therapy for cystic fibrosis (CF) patients who carry class III/IV mutations (e.g., G551D). In combination with corrector GLPG2222, this potentiator will also be developed for patients affected by the F508del mutation, the most prevalent mutation in CF patients. This achievement triggers a milestone payment of $10 million from AbbVie. read more

Esperite N.V. appoints EY as external auditor

19.12.2014

Esperite N.V. (Euronext: ESP, 'Esperite', or 'the Group'), the European leader in stem cells cryopreservation, now entering the fields of predictive medicine and translational regenerative medicine R&D, announces that all resolutions of today's extra-ordinary general meeting of shareholders ("EGM") were passed and that EY Accountants LLP was appointed as external auditor for a term of 1-year read more

Tiende aflevering van Z Life Sciences over de activiteiten van Flanders Investment & Trade en Biocartis gemist? Bekijk de reportage hier opnieuw!

19.12.2014

De life sciences sector zoekt oplossingen voor onze gezondheid, landbouw en voeding. De sector telt in Vlaanderen zo’n 250 ondernemingen en 75 000 medewerkers in beloftevolle start-ups, internationale bedrijven, gerenommeerde onderzoeksinstellingen en ondersteunende organisaties.Z life sciences kijkt achter de schermen van deze innovatieve sector in volle expansie. Elke donderdag op Kanaal Z. read more

Cardio3 BioSciences will be present at Oddo Midcap Forum

17.12.2014

ImmunXperts s.a. today announced it has successfully raised in excess of one million USD of seed financing. read more

ABLYNX OPENS RECRUITMENT FOR FIRST-IN-INFANT PHASE IIa STUDY WITH ITS ANTI-RSV NANOBODY, ALX-0171

17.12.2014

Ablynx [Euronext Brussels: ABLX] today announced that it has opened recruitment in the initial clinical centres for the first-in-infant Phase IIa study with ALX-0171, administered through inhalation. ALX-0171 is a trivalent Nanobody developed for the treatment of Respiratory Syncytial Virus (RSV) infections. Currently, there are no widely used anti-RSV therapeutic drugs available. read more

ImmunXperts successfully raises in excess of 1 Million USD in Equity and Bank financing - Launch of a new service provider for biotherapeutics

16.12.2014

ImmunXperts s.a. today announced it has successfully raised in excess of one million USD of seed financing. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print